BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11840

539551

NH

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NARAYANA HRUDAYALAYA LTD. performance

Today’s low

Today’s high

₹ 1744.60 ₹ 1800.00
₹ 1760.50

52 week low

52 week high

₹ 1080.00 ₹ 1871.60
₹ 1760.50

Open Price

₹ 1765.80

Prev. Close

₹ 1775.80

Volume (Shares)

314492.00

Total traded value

₹ 5536.63

Upper Circuit

₹ 2130.90

Lower Circuit

₹ 1420.70

info

NARAYANA HRUDAYALAYA LTD. Share Price Update

As of the latest trading session, NARAYANA HRUDAYALAYA LTD. share price is currently at ₹ 1745.1, which is down by ₹ -30.70 from its previous closing. Today, the stock has fluctuated between ₹ 1744.60 and ₹ 1800.00. Over the past year, NARAYANA HRUDAYALAYA LTD. has achieved a return of 36.78 %. In the last month alone, the return has been 4.99 %. Read More...

NARAYANA HRUDAYALAYA LTD. fundamentals


  • Market cap (Cr)

    35,663.00

  • P/E Ratio (TTM)

    83.75

  • Beta

    0.49

  • Book Value / share

    95.32

  • Return on equity

    25.66%

  • EPS (TTM)

    21.00

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    79.22

info icon alternate text
  • Market cap (Cr)

    35,707.96

  • P/E Ratio (TTM)

    83.75

  • Beta

    0.50

  • Book Value / share

    95.32

  • Return on equity

    25.66%

  • EPS (TTM)

    21.00

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    79.22

info icon alternate text

NARAYANA HRUDAYALAYA LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 865.04
Operating Expense 772.25
Net Profit 79.22
Net Profit Margin (%) 9.15
Earnings Per Share (EPS) 3.90
EBITDA 165.31
Effective Tax Rate (%) 21.90
Particulars SEP 2024 (Values in Cr)
Revenue 934.29
Operating Expense 813.73
Net Profit 105.53
Net Profit Margin (%) 11.29
Earnings Per Share (EPS) 5.20
EBITDA 195.70
Effective Tax Rate (%) 21.10
Particulars JUN 2024 (Values in Cr)
Revenue 871.76
Operating Expense 774.92
Net Profit 86.41
Net Profit Margin (%) 9.91
Earnings Per Share (EPS) 4.25
EBITDA 170.23
Effective Tax Rate (%) 21.79
Particulars MAR 2024 (Values in Cr)
Revenue 846.31
Operating Expense 748.70
Net Profit 158.09
Net Profit Margin (%) 18.67
Earnings Per Share (EPS) 7.78
EBITDA 245.89
Effective Tax Rate (%) 15.46
Particulars DEC 2023 (Values in Cr)
Revenue 770.57
Operating Expense 686.49
Net Profit 78.66
Net Profit Margin (%) 10.20
Earnings Per Share (EPS) 3.87
EBITDA 148.43
Effective Tax Rate (%) 16.91
Particulars MAR 2024 (Values in Cr)
Book Value / Share 141.17
ROE % 31.49
ROCE % 25.00
Total Debt to Total Equity 0.50
EBITDA Margin 24.76
Particulars MAR 2023 (Values in Cr)
Book Value / Share 104.36
ROE % 33.51
ROCE % 29.27
Total Debt to Total Equity 0.44
EBITDA Margin 23.11
Particulars MAR 2022 (Values in Cr)
Book Value / Share 72.91
ROE % 26.23
ROCE % 21.71
Total Debt to Total Equity 0.59
EBITDA Margin 18.62
Particulars MAR 2021 (Values in Cr)
Book Value / Share 54.89
ROE % -0.71
ROCE % 1.43
Total Debt to Total Equity 0.79
EBITDA Margin 8.37
Particulars MAR 2020 (Values in Cr)
Book Value / Share 55.66
ROE % 10.74
ROCE % 11.26
Total Debt to Total Equity 0.80
EBITDA Margin 14.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 90.11
ROE % 25.66
ROCE % 22.28
Total Debt to Total Equity 0.50
EBITDA Margin 22.35
Particulars MAR 2023 (Values in Cr)
Book Value / Share 71.93
ROE % 19.72
ROCE % 22.54
Total Debt to Total Equity 0.44
EBITDA Margin 19.86
Particulars MAR 2022 (Values in Cr)
Book Value / Share 60.02
ROE % 11.54
ROCE % 14.27
Total Debt to Total Equity 0.47
EBITDA Margin 15.32
Particulars MAR 2021 (Values in Cr)
Book Value / Share 53.39
ROE % -6.98
ROCE % -4.14
Total Debt to Total Equity 0.51
EBITDA Margin 3.00
Particulars MAR 2020 (Values in Cr)
Book Value / Share 57.12
ROE % 5.81
ROCE % 8.95
Total Debt to Total Equity 0.47
EBITDA Margin 12.82
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 416.45
Total Assets 5624.58
Total Liabilities 5624.58
Total Equity 2885.08
Share Outstanding 204360804
Price to Book Ratio 14.21
Return on Assets (%) 14.03
Return on Capital (%) 18.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 379.88
Total Assets 4162.09
Total Liabilities 4162.09
Total Equity 2132.42
Share Outstanding 204360804
Price to Book Ratio 10.76
Return on Assets (%) 14.56
Return on Capital (%) 20.94
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 172.16
Total Assets 3130.53
Total Liabilities 3130.53
Total Equity 1489.36
Share Outstanding 204360804
Price to Book Ratio 12.44
Return on Assets (%) 10.92
Return on Capital (%) 16.81
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 132.05
Total Assets 2770.01
Total Liabilities 2770.01
Total Equity 1120.82
Share Outstanding 204360804
Price to Book Ratio 7.61
Return on Assets (%) -0.51
Return on Capital (%) -0.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 114.77
Total Assets 2891.06
Total Liabilities 2891.06
Total Equity 1136.49
Share Outstanding 204360804
Price to Book Ratio 4.33
Return on Assets (%) 4.11
Return on Capital (%) 6.73
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 232.47
Total Assets 3492.76
Total Liabilities 3492.76
Total Equity 1840.21
Share Outstanding 204360804
Price to Book Ratio 14.21
Return on Assets (%) 12.15
Return on Capital (%) 15.37
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 197.68
Total Assets 2774.72
Total Liabilities 2774.72
Total Equity 1468.74
Share Outstanding 204360804
Price to Book Ratio 10.76
Return on Assets (%) 9.57
Return on Capital (%) 13.2
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 113.26
Total Assets 2282.49
Total Liabilities 2282.49
Total Equity 1225.08
Share Outstanding 204360804
Price to Book Ratio 12.44
Return on Assets (%) 5.85
Return on Capital (%) 8.31
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 56.19
Total Assets 2100.65
Total Liabilities 2100.65
Total Equity 1089.64
Share Outstanding 204360804
Price to Book Ratio 7.61
Return on Assets (%) -3.74
Return on Capital (%) -5.32
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 52.26
Total Assets 2220.17
Total Liabilities 2220.17
Total Equity 1165.87
Share Outstanding 204360804
Price to Book Ratio 4.33
Return on Assets (%) 0.00
Return on Capital (%) 0
Particulars MAR 2024 (Values in Cr)
Net Income 789.62
Cash from Operations 1157.82
Cash from Investing -1457.94
Cash from Financing 488.45
Net change in Cash 97.11
Free Cash Flow 2128.42
Particulars MAR 2023 (Values in Cr)
Net Income 606.56
Cash from Operations 1170.31
Cash from Investing -1174.10
Cash from Financing 87.74
Net change in Cash -1.80
Free Cash Flow 1692.35
Particulars MAR 2022 (Values in Cr)
Net Income 342.12
Cash from Operations 551.78
Cash from Investing -266.91
Cash from Financing -158.94
Net change in Cash 59.15
Free Cash Flow 802.46
Particulars MAR 2021 (Values in Cr)
Net Income -14.29
Cash from Operations 250.69
Cash from Investing -112.98
Cash from Financing -193.64
Net change in Cash -2.36
Free Cash Flow 320.79
Particulars MAR 2020 (Values in Cr)
Net Income 119.05
Cash from Operations 509.33
Cash from Investing -188.54
Cash from Financing -246.94
Net change in Cash 7.85
Free Cash Flow 625.21
Particulars MAR 2024 (Values in Cr)
Net Income 424.51
Cash from Operations 614.02
Cash from Investing -760.63
Cash from Financing 237.26
Net change in Cash 18.75
Free Cash Flow 1119.29
Particulars MAR 2023 (Values in Cr)
Net Income 265.63
Cash from Operations 593.26
Cash from Investing -621.22
Cash from Financing 64.77
Net change in Cash -40.19
Free Cash Flow 838.07
Particulars MAR 2022 (Values in Cr)
Net Income 133.59
Cash from Operations 301.24
Cash from Investing -117.04
Cash from Financing -56.61
Net change in Cash 72.33
Free Cash Flow 482.07
Particulars MAR 2021 (Values in Cr)
Net Income -78.67
Cash from Operations 73.60
Cash from Investing -11.81
Cash from Financing -114.25
Net change in Cash -2.64
Free Cash Flow 109.27
Particulars MAR 2020 (Values in Cr)
Net Income 0.00
Cash from Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash 0.00
Free Cash Flow 0.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 76.41 13.35 100103.60 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 83.30 12.22 100103.60 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00

NARAYANA HRUDAYALAYA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1760.50 -0.86 redarrow
red-green-graph indicator
6 Bearish
10 Bullish
  • 5 Days 1780.40
  • 26 Days 1720.10
  • 10 Days 1776.90
  • 50 Days 1634.40
  • 12 Days 1771.50
  • 100 Days 1520.80
  • 20 Days 1743.30
  • 200 Days 1408.80
1787.17 PIVOT

First Support

1759.23

First Resistance

1803.73

Second Support

1742.67

Second Resistance

1831.67

Third Support

1714.73

Third Resistance

1848.23

RSI

57.11

ADX

16.14

MACD

51.43

Williams % R

-49.74

Commodity Channel Index (CCI)

27.87

Date

2025-04-30

Week

152777.00

Same Day

157148.00

Month

230430.00

1 Year

0.49

3 Year

0.44

Over 1 Month

4.99%

down

Over 1 Year

36.78%

down

Over 3 Months

34.98%

down

Over 3 Years

36.34%

down

Over 6 Months

44.00%

down

Over 5 Years

44.48%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

NARAYANA HRUDAYALAYA LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
17.96%
Promoter Holdings
63.85%
FII
9.66%
DII
8.52%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shakuntala Shetty 7.2301135E7 (35.38%) Shareholding of Promoter and Promoter Group
Devi Prasad Shetty 2.3828411E7 (11.66%) Shareholding of Promoter and Promoter Group
Anesh Shetty 1.021804E7 (5.0%) Shareholding of Promoter and Promoter Group
Varun Shetty 1.021804E7 (5.0%) Shareholding of Promoter and Promoter Group
Viren Prasad Shetty 1.021804E7 (5.0%) Shareholding of Promoter and Promoter Group
Kiran Mazumdar Shaw 4705671.0 (2.3%) Public Shareholding
Narayana Health Academy Private Limited 3702064.0 (1.81%) Shareholding of Promoter and Promoter Group
Nippon Life India Trustee Ltd-a/c Nippon India Pha 3312466.0 (1.62%) Public Shareholding
Axis Mutual Fund Trustee Limited A/c Axis Mutual F 2795653.0 (1.37%) Public Shareholding
Dsp Small Cap Fund 2253577.0 (1.1%) Public Shareholding
Sbi Life Insurance Co. Ltd 2202000.0 (1.08%) Public Shareholding
Franklin Templeton Investment Funds - Franklin Ind 2155564.0 (1.05%) Public Shareholding
Parag Parikh Flexi Cap Fund 2100704.0 (1.03%) Public Shareholding
Ameya Shetty 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

NARAYANA HRUDAYALAYA LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
07 Jul 2023 2.5 Final 07 Jul 2023 Equity shares
22 Aug 2022 1.0 Final 23 Aug 2022 Equity shares
11 Mar 2020 1.0 Interim 12 Mar 2020 Equity shares
01 Aug 2019 1.0 Final 03 Aug 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
07 Jul 2023 2.5 Final 07 Jul 2023 Equity shares
22 Aug 2022 1.0 Final 23 Aug 2022 Equity shares
11 Mar 2020 1.0 Interim 12 Mar 2020 Equity shares
01 Aug 2019 1.0 Final 03 Aug 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

NARAYANA HRUDAYALAYA LTD. Share Price

Narayana Hrudayalaya Limited was incorporated on 19 July 2000 by Dr. Devi Prasad Shetty as its Founder. The Company is primarily engaged in the business of rendering medical and healthcare services. It has a network of multispeciality, and super speciality hospitals spread across multiple locations. The Company owns and operates certain hospitals and also enters into management agreements
with hospitals under which the Company acquires the operating control of the hospitals.

During the financial year ended 31 March 2016, Company acquired the entire remaining 26% in Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL) from Infrastructure Development Corporation (Karnataka) Limited (IDECK) by paying Rs 3,025.60 Lacs as total purchase consideration to make NHSHPL as its wholly owned subsidiary.

During the year under review, the company through its wholly owned subsidiary entered into an agreement with prominent Kenyan doctors and couple of leading international financial institutions to establish a multi-specialty hospital in Nairobi, Kenya. The company through its wholly owned subsidiary would initially own 26% equity stake in the operational entity for a consideration of USD 1.325 million. The multi-specialty hospital will be a state of the art tertiary care facility poised to cater to patients across different specialties. The 130 bedded hospital will provide affordable quality care that Narayana stands for, to the patients from Kenya and neighbouring African countries.

During the year under review, the company received National Accreditation Board for Hospitals & Healthcare Providers (NABH) accreditation for 5 new units viz. HSR, Guwahati, Ahmedabad, Jamshedpur and Mysore.

Asia Healthcare Development Limited (AHDL) was a wholly owned subsidiary of the Company which was engaged in the business of operation of hospitals, clinics, health centers, nursing homes and other related activities. The Company was sold in November 2016 to Lila Hospitals Private Limited by executing a Share Purchase Agreement for the sale of all its shares for a consideration of Rs. 38.34 lacs.

The promoters and promoter group of the company other shareholders (JP Morgan Mauritius Holdings, Ambadevi Mauritius Holdings, Ashoka Investment Holdings) offloaded a total of 2.45 crore equity shares of Narayana Hrudayalaya by way of an initial public offer (IPO). The IPO was open for subscription during the period from 17 to 21 December 2015. There was no fresh issue of shares from the company. The company got its securities listed on BSE Limited and on National Stock Exchange of India Limited on 6 January 2016.

During the year ended 31st March 2016, the Company completed the Initial Public Offering (IPO) through an offer for sale by existing shareholders to the extent of 24,523,297 equity shares of face value of Rs10 each for a cash price of Rs 250 per equity share including a premium of Rs 240 per equity share, of 6,287,978 equity shares by Ashoka Investment Holdings Limited, 1,886,455 equity shares by Ambadevi Mauritius Holdings Limited, 12,261,648 equity shares by JP Morgan Mauritius Holdings IV Limited, 2,043,608 equity shares by Dr. Devi Prasad Shetty and 2,043,608 equity shares by Shakuntala Shetty aggregating to Rs 6130.82 million and the equity shares of the Company were listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited on 6th January 2016.At the beginning of the financial year ended 31 March 2017, Narayana Hrydayalaya made significant investments by acquiring NewRise Healthcare Private Limited from Panacea Biotech Limited at an enterprise value of Rs 180 crore. On the organic route, the company started fiscal 2016-17 with the commissioning of its super speciality facility at Kakriyal, Jammu (established in partnership with Shri Mata Vaishno Devi Shrine Board). The 230 bedded facility is a state-of-the-art tertiary care facility catering to patients across 20 different specialities with a particular focus on cardiac sciences and oncology

Pursuant to a Share Purchase Agreement executed in November 2016, Asia Healthcare Development Limited was sold to Lila Hospitals Private Limited. Narayana Hrydayalaya's subsidiary Narayana Hrudayalaya Hospitals Malaysia Sdn Bhd (Narayana Malaysia) filed an application for voluntary liquidation, pursuant to Section 257(1) of the Companies Act, 1965 of Malaysia in January 2017.

During the financial year ended 31 March 2017, the company launched a dedicated 30 bedded platinum wing in Mazumdar Shaw Medical Centre, Bengaluru to offer world-class services and comfort in line with international standards of dedicated care and hospitality. During the year under review, the company partnered with Cisco to offer affordable remote diagnostic capabilities; this digital telemedicine solution would deliver advanced specialized healthcare services remotely in various parts of the country.

Narayana Hrydayalaya's wholly owned subsidiary Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL) entered into a Healthcare Services Agreement in March 2017 with Dharamshila Cancer Foundation and Research Centre for operating a hospital in New Delhi. NHSHPL is engaged in the business of operating and maintaining hospitals, clinics, health centers, nursing homes and other related activities.

Towards the beginning the financial year ended 31 March 2018, the company commissioned SRCC Children's Hospital at Haji Ali Park, Mahalaxmi in Mumbai. The facility is operated and managed by Narayana Hrydayalaya and backed by SRCC, an institution renowned for serving the needs of children from all sections of society. SRCC Children's Hospital is the company's maiden foray in Mumbai and a well-calibrated step in line with the group strategy to reinforce its presence across selected regional clusters. Narayana Hrydayalaya also acquired) a ~230 bedded near complete hospital at Gurugram in early 2017-18.

During the financial year ended 31 March 2018, NewRise Healthcare Private Limited (NRHPL) was merged with the company vide Regional Director's Order dated 4 October 2017. NRHPL was a wholly owned subsidiary of the company which was acquired from Panacea Biotech Limited during the year under review.

The company commissioned 2nd LINAC at Westbank in June 2017. The wholly owned subsidiary company, Narayana Cayman Holdings Ltd. was merged with the step-down subsidiary, Health City Cayman Islands Ltd. through Scheme of Merger effective April 1, 2021.

In 2023, The Health City Cayman Islands Ltd. (HCCI) acquired the 100% Ordinary Shares in the ENT in Cayman Ltd. on 3rd March, 2023. Accordingly, ENT in Cayman Ltd. was made a 100% step-down subsidiary of the Company.

In 2022-23, the Company through a Business Transfer Agreement (BTA) with hiva and Shiva Orthopaedic Hospital Private Limited acquired its Orthopaedic and Trauma Hospital effective from October 1, 2022 as a going concern on slump sale basis for an aggregate cash consideration of Rs 200 Crores. The Company launched its first ever Cadaveric Liver & Kidney Transplant at DNSH, Delhi. Narayana Multispecialty Hospital, Jaipur performed its First Liver Transplant in FY23. Narayana Multispecialty Hospital, Jaipur commissioned its new LINAC Machine, further bolstering its capabilities in the field of Oncology. Narayana Institute of Cardiac Sciences (NICS), in Health City, Bengaluru operationalized three new Operating Rooms, expanding its capacity to serve patients in need of surgical procedures. Mazumdar Shah Medical Centre (MSMC), Bengaluru acquired the Sparsh Hospital unit it its Health City premises in Bommasandra and expanded its scope of clinical services by launching the Dept. of Orthopaedics & Joint Replacement. MSMC went on to become the largest Bone Marrow Transplant (BMT) facility in India, with a total capacity of 35 Bone Marrow Transplant (BMT) beds. Dharamshila Narayana Superspecialty Hospital (DNSH) in Delhi expanded its clinical services by adding Da Vinci Robot and launching Robotic GI Surgery, providing patients with access to cutting-edge surgical technology. The Unit also upgraded its Radiation Therapy system to Versa HD platform, installed an Advanced Nurse Call Bell System with Patient Tracker & Announcement Facility and, conducted its first successful Cadaveric Liver Transplant in the year.

In 2024, the radiation oncology block of the proposed new greenfield hospital at Camana Bay got commissioned. Operationalizing the Ortho
& Trauma Centre at our Health City campus marked a pivotal achievement during the year. In the realm of Neurosciences, the hospital has established itself as a pioneer with four state-of-the-art Interventional Neurology Programs. Annually, the Hospital performed over 5,000 neurosurgical surgeries. The Hospital made a history on September 21, 2023, by conducting a record-breaking 3,797 electrocardiograms (ECGs) in a single day at Health City, Bangalore. The primary objective of this endeavour was to raise awareness about health screening and the importance of regular check-ups in preventing heart diseases. By setting this unprecedented record, Narayana Health has
established a new standard in cardiac care, showcasing both its technical expertise and commitment to accessible healthcare.

In 2024, Narayana Hospital-RN Tagore Hospital, Kolkata performed Trans-axillary Perceval Plus Suture-less Aortic Valve Replacement
using central cannulation technique making it one of the rarely performed procedures. Narayana Hospital Ahmedabad performed Gujarat's first PDA Device Closure using 4/2 Amplatzer (Piccolo) Occluder Device on a 30-day-old weighing 900gms. Robotic Trans Anal Minimal Invasive Surgery (R - TAMIS) - rare & specialized surgery done for resection of selected rectal tumors during the year. Narayana Institute of Cardiac Sciences, Narayana Health City commissioned two new Cath Labs in FY24. Mazumdar Shaw Medical Center, Narayana Health City, Department of Orthopaedics & Trauma, started Hand Upper Limb Services & Elbow Arthroscopy in FY24. Shri Mata Vaishno Devi Narayana
Superspecialty Hospital Katra started Day Care Services in Jammu OPD that included 10 beds for chemotherapy and 8 for dialysis. Dharamshila Narayana Hospital Delhi upgraded to Elekta Synergy Versa HD- a radiotherapy platform that uses a linear accelerator to treat tumors with sub-millimeter accuracy. Narayana Hospital Jaipur expanded its service spectrum by starting Radiation Oncology Services in the unit during the year.

Parent organization Indian Private
NSE symbol NH
Founded 2000
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Narayana Hrudayalaya Ltd?

Answer Field

The share price of Narayana Hrudayalaya Ltd for NSE is ₹ 1745.1 and for BSE is ₹ 1747.3.

What is the Market Cap of Narayana Hrudayalaya Ltd?

Answer Field

The market cap of Narayana Hrudayalaya Ltd for NSE is ₹ 3,56,63.00 Cr. and for BSE is ₹ 3,57,07.96 Cr. as of now.

What is the 52 Week High and Low of Narayana Hrudayalaya Ltd?

Answer Field

The 52 Week High and Low of Narayana Hrudayalaya Ltd for NSE is ₹ 1871.60 and ₹ 1080.00 and for BSE is ₹ 1872.85 and ₹ 1087.80.

How to Buy Narayana Hrudayalaya Ltd share?

Answer Field

You can trade in Narayana Hrudayalaya Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Narayana Hrudayalaya Ltd?

Answer Field

The 1 year returns on the stock has been 36.78%.

What is the Current Share Price of Narayana Hrudayalaya Ltd?

Answer Field

Narayana Hrudayalaya Ltd share price is for NSE ₹ 1745.1 & for BSE ₹ 1747.3 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Narayana Hrudayalaya Ltd Share?

Answer Field

The market cap of Narayana Hrudayalaya Ltd for NSE ₹ 3,56,63.00 & for BSE ₹ 3,57,07.96 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Narayana Hrudayalaya Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Narayana Hrudayalaya Ltd share is 83.75.

What is the PB ratio of Narayana Hrudayalaya Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Narayana Hrudayalaya Ltd share is 95.32.

How to Buy Narayana Hrudayalaya Ltd Share?

Answer Field

You can trade in Narayana Hrudayalaya Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Narayana Hrudayalaya Ltd Share on Bajaj Broking App?

Answer Field

To buy Narayana Hrudayalaya Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Narayana Hrudayalaya Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|